NCT06088290: Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
- State
- Under way
- Phase
- Phase 3
- People
- 469 taking part
- Started
- 21 Sep 2023
- Primary completion
- 30 Aug 2029
- Arms
- Doxorubicin (Dose A) + Lurbinectedin (Dose B), Doxorubicin (Dose C) + Lurbinectedin (Dose D)
- Results
- None posted
- 21 Sep 2023: Trial started
- 18 Oct 2023: Trial registered